.jpg)
.jpg)
Artificial intelligence has helped researchers discover a naturally occurring molecule that could rival Ozempic for weight loss, marking a significant breakthrough in obesity treatment.
Scientists at Stanford Medicine used AI to identify a 12-amino-acid peptide, named BRP (BRINP2-related peptide), which has demonstrated powerful appetite-suppressing and fat-reducing effects in animal studies.
BRP has been detected in human cerebrospinal fluid, indicating its presence and potential role in the central nervous system. It can reduce food intake in mice and pigs and has proven anti-obesity effects, NovoPro Labs explained.
According to the study published in the journal Nature, lean mice that received BRP exhibited a 50% reduction in food intake within an hour, while obese mice experienced substantial fat loss after being injected with BRP over 14 days. The mice also showed improved glucose and insulin tolerance.
Unlike semaglutide, the active ingredient in Ozempic, BRP appears to act specifically on the hypothalamus, a brain region that regulates appetite and metabolism. Researchers also noted that the peptide achieved these effects without the gastrointestinal side effects commonly associated with GLP-1 receptor agonists.
“The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues,” Katrin Svensson, PhD., assistant professor of pathology at Stanford University, told Stanford Medicine.
“That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism.”
The discovery of BRP highlights AI's growing role in medicine and drug discovery, as the algorithm used by Stanford Medicine was able to rapidly identify the peptide from over 20,000 human protein-coding genes in their database.
AI has increasingly been leveraged in pharmaceutical research to accelerate the development of new treatments, reducing the time and cost associated with traditional drug discovery methods.
“The algorithm was absolutely key to our findings,” Svensson added.
Despite the promising results in animal models, BRP has not yet been tested in humans. Clinical trials will be necessary to determine its safety and effectiveness in humans before it can be considered a viable alternative to Ozempic or similar medications.
Disclaimer:
The information provided here is for entertainment and educational purposes only. It is not intended to substitute medical professional advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Visit the disclaimer link for more details: www.biohackyourself.com/termsanddisclaimers.
コメント